LEADER 04582nam 22007095 450 001 9910298272403321 005 20200629202918.0 010 $a94-017-9732-3 024 7 $a10.1007/978-94-017-9732-0 035 $a(CKB)3710000000372248 035 $a(EBL)1998716 035 $a(OCoLC)904338879 035 $a(SSID)ssj0001465023 035 $a(PQKBManifestationID)11903531 035 $a(PQKBTitleCode)TC0001465023 035 $a(PQKBWorkID)11459990 035 $a(PQKB)11521693 035 $a(DE-He213)978-94-017-9732-0 035 $a(MiAaPQ)EBC1998716 035 $a(PPN)184888972 035 $a(EXLCZ)993710000000372248 100 $a20150302d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aKinesins and Cancer /$fedited by Frank Kozielski, FSB 205 $a1st ed. 2015. 210 1$aDordrecht :$cSpringer Netherlands :$cImprint: Springer,$d2015. 215 $a1 online resource (276 p.) 300 $aDescription based upon print version of record. 311 $a94-017-9731-5 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aPreface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy?.- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target.-Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index. 330 $aThis interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail. 606 $aCancer research 606 $aCell biology 606 $aMedicinal chemistry 606 $aProteins  606 $aOncology   606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aCell Biology$3https://scigraph.springernature.com/ontologies/product-market-codes/L16008 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aProtein-Ligand Interactions$3https://scigraph.springernature.com/ontologies/product-market-codes/L14060 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aCancer research. 615 0$aCell biology. 615 0$aMedicinal chemistry. 615 0$aProteins . 615 0$aOncology  . 615 14$aCancer Research. 615 24$aCell Biology. 615 24$aMedicinal Chemistry. 615 24$aProtein-Ligand Interactions. 615 24$aOncology. 676 $a572/.6 702 $aKozielski$b FSB, Frank$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298272403321 996 $aKinesins and Cancer$92500499 997 $aUNINA